Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
u/2plus2_equals_5 ·
Reddit — r/stocks
· April 30, 2026 at 11:52
· ⬆ 30 pts
· 💬 10 comments
| View on Reddit ↗
No analysis available.
Score30
Comments10
Upvote %92%
▶ Full Post Text
Eli Lilly crushed Q1 and raised guidance again.
EPS: **$8.55 vs $6.66 expected**
Revenue: **$19.8B vs $17.62B expected** (+56% YoY)
Stock up **5% premarket**
Main driver was GLP-1 demand:
**Mounjaro:** $8.66B revenue (+125%), beat estimates
**Zepbound:** $4.16B US revenue (+80%), also beat
Lilly now expects **2026 revenue of $82B–$85B** (was $80B–$83B) and adjusted EPS of **$35.50–$37** (was $33.50–$35).
They currently hold about **60% of the US obesity/diabetes GLP-1 market**, ahead of Novo at 39%.
Even with lower prices, demand keeps ripping. New obesity pill Foundayo just launched, so next earnings call will probably focus on whether it can become another monster product.